The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Abuelbeh, Ibrahim; Abu-Shawer, Osama; Abu-Shawer, Mohammad; Alkderat, Murad; Safi, Mohannad; Alwazani, Abdullah; Alkhatib, Ala’a Aldeen; Abu-Hussein, Bilal; Aladawi, Mohammad; Ismail, Saeed; Altamimi, Tamer Salhab; Hejleh, Taher Abu

doi:10.1055/s-0042-1749613

Cited by 2 publications

(3 citation statements)

References 24 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and correlates with high LDH serum level [ 9 , 10 , 12 ]. Although NLR has been associated with the presence of brain metastases [ 16 , 17 ], we were not able to find a correlation between high NLR and the presence of brain metastases, conversely our results detected a NLR even higher in patients without brain metastases. Indeed, NLR impacts the PFS and OS of patients without brain metastases with a higher effect than those with such metastases.…”

Section: Discussioncontrasting

confidence: 99%

“…• NA 18 (23) As high NLR is known to be associated with brain metastases present at baseline or subsequently [16,17], we decided to rule out a possible role of brain metastases in the negative correlation of NLR with prognostic parameters, and the subgroups of patients with and without brain metastases were analyzed. As shown in Fig.…”

Section: Response Disease and Survival Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Mallardo,

Fordellone,

White

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb–IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis. Results The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of the presence of brain metastases. The transcriptomic analysis showed that high baseline NLR is associated with a characteristic gene signature CCNA1, LDHA and IL18R1, which correlates with inflammation and tumorigenesis. Conversely, low baseline NLR is associated with the signature CD3, SH2D1A, ZAP70 and CD45RA, linked to the immune-activation. The genes positively associated with NLR (CD39 (ENTPD1), PTEN, MYD88, MMP9 and LDH) are involved in processes of immunosuppression, inflammation and tumor-promoting activity. Increased expression of CD39 correlated with TGFβ2, a marker of the N2 neutrophils with immunosuppressive activity. Conclusions These results suggest that increasing NLR is associated with an increased neutrophil population, with polarization to the N2 phenotype, and this process may be the basis for the negatively prognostic role of NLR.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Response Disease and Survival Outcomesmentioning

confidence: 99%

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Mallardo,

Fordellone,

White

et al. 2023

J Transl Med

View full text Add to dashboard Cite

show abstract

“…2B), respectively. As high NLR is known to be associated with brain metastases present at baseline or subsequently [16,17], we decided to rule out a possible role of brain metastases in the negative correlation of NLR with prognostic parameters, and the subgroups of patients with and without brain metastases were analyzed.…”

Section: Resultsmentioning

confidence: 99%

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Mallardo

Fordellone

White

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb–IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis. Results The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of the presence of brain metastases. The transcriptomic analysis showed that high baseline NLR is associated with a characteristic gene signature CCNA1, LDHA and IL18R1, which is correlates with inflammation and tumorigenesis. Conversely, low baseline NLR is associated with the signature CD3, SH2D1A, ZAP70 and CD45RA, linked to the immune-activation. The genes positively associated with NLR (CD39 (ENTPD1), PTEN, MYD88, MMP9 and LDH) are involved in processes of immunosuppression, inflammation and tumor-promoting activity. Increased expression of CD39 correlated with TGFβ2, a marker of the N2 neutrophils with immunosuppressive activity. Conclusions These results suggest that increasing NLR is associated with an increased neutrophil population, with polarization to the N2 phenotype, and this process may be the basis for the negatively prognostic role of NLR.

show abstract

The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Cited by 2 publications

References 24 publications

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Contact Info

Product

Resources

About